Literature DB >> 21330456

Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis.

Emer P Reeves1, Michael Williamson, Shane J O'Neill, Peter Greally, Noel G McElvaney.   

Abstract

RATIONALE: Inflammation within the cystic fibrosis (CF) lung is mediated by inflammatory chemokines, such as IL-8. IL-8 is protected from proteolytic degradation in the airways by binding to glycosaminoglycans, while remaining active. Evidence that increased hypertonicity of airway secretions induced by hypertonic saline treatment alters levels of IL-8 is lacking.
OBJECTIVES: To investigate the antiinflammatory effect of hypertonic saline (HTS) treatment within the CF lung by focusing on IL-8.
METHODS: Degradation of IL-8 in CF lung secretions after treatment with glycosaminoglycan lyases and HTS was analyzed by Western blot analysis and ELISA. The ex vivo chemotactic activity of purified neutrophils in response to CF airway secretions was evaluated post nebulization of HTS (7% saline).
MEASUREMENTS AND MAIN RESULTS: In vivo CF bronchoalveolar lavage fluid (BALF) IL-8 levels were significantly higher than the control group (P < 0.05). Digesting glycosaminoglycans in CF BALF displaced IL-8 from glycosaminoglycan matrices, rendering the chemokine susceptible to proteolytic cleavage. High sodium concentrations also liberate IL-8 in CF BALF in vitro, and in vivo in CF sputum from patients receiving aerosolized HTS, resulting in degradation of IL-8 and decreased neutrophil chemotactic efficiency.
CONCLUSIONS: Glycosaminoglycans possess the ability to influence the chemokine profile of the CF lung by binding and stabilizing IL-8, which promotes neutrophil chemotaxis and activation. Nebulized hypertonic saline treatment disrupts the interaction between glycosaminoglycans and IL-8, rendering IL-8 susceptible to proteolytic degradation with subsequent decrease in neutrophil chemotaxis, thereby facilitating resolution of inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330456     DOI: 10.1164/rccm.201101-0072OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

1.  Repurposing tromethamine as inhaled therapy to treat CF airway disease.

Authors:  Mahmoud H Abou Alaiwa; Janice L Launspach; Kelsey A Sheets; Jade A Rivera; Nicholas D Gansemer; Peter J Taft; Peter S Thorne; Michael J Welsh; David A Stoltz; Joseph Zabner
Journal:  JCI Insight       Date:  2016-06-02

2.  Differences in innate immune response gene regulation in the middle ear of children who are otitis prone and in those not otitis prone.

Authors:  Ravinder Kaur; Janet Casey; Michael Pichichero
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

3.  Syndecan-4 regulates early neutrophil migration and pulmonary inflammation in response to lipopolysaccharide.

Authors:  Yoshinori Tanino; Mary Y Chang; Xintao Wang; Sean E Gill; Shawn Skerrett; John K McGuire; Suguru Sato; Takefumi Nikaido; Tetsuhito Kojima; Mitsuru Munakata; Steve Mongovin; William C Parks; Thomas R Martin; Thomas N Wight; Charles W Frevert
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-15       Impact factor: 6.914

Review 4.  Update in cystic fibrosis 2012.

Authors:  Christopher H Goss; Felix Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2013-05-01       Impact factor: 21.405

5.  Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13.

Authors:  Max Wohlauer; Ernest E Moore; Christopher C Silliman; Miguel Fragoso; Fabia Gamboni; Jeffrey Harr; Frank Accurso; Frank Wright; James Haenel; David Fullerton; Anirban Banerjee
Journal:  Crit Care Med       Date:  2012-09       Impact factor: 7.598

6.  Nebulized thiocyanate improves lung infection outcomes in mice.

Authors:  J D Chandler; E Min; J Huang; D P Nichols; B J Day
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

7.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

8.  Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease.

Authors:  Simon Y Graeber; Zhe Zhou-Suckow; Jolanthe Schatterny; Stephanie Hirtz; Richard C Boucher; Marcus A Mall
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

9.  Pharmacotherapy challenges of Fontan-associated plastic bronchitis: a rare pediatric disease.

Authors:  Kristina Brooks; Regine L Caruthers; Kurt R Schumacher; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2013-05-17       Impact factor: 4.705

10.  Immunophenotyping and protein profiling of Fontan-associated plastic bronchitis airway casts.

Authors:  Jennifer Racz; Gerta Mane; Michael Ford; Lindsay Schmidt; Jeffrey Myers; Theodore J Standiford; Kurt R Schumacher; Carlen Fifer; Mark W Russell; Kathleen A Stringer
Journal:  Ann Am Thorac Soc       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.